Distribution of inpatient cost per day (A) and total cost (B) for allogeneic HCT recipients with TA-TMA (n = 137) according to risk stratification. (A) HR-TA-TMA (n = 55) vs SR-TA-TMA (n = 82): cost per day from day 15 to day 365 after HCT (P = .002). Patients were stratified as having high risk if they had sC5b-9 level > the upper limit of normal and proteinuria > 2 mg/mg or either elevated sC5b-9 level or proteinuria and multiorgan dysfunction. (B) HR-TA-TMA (n = 55) vs SR-TA-TMA (n = 82): total cost (P = .001).